Fig. 1

FKBP5 methylation associated with cardiometabolic risk in individuals with diabetes. a Greater percent DNA methylation of the FKBP5 intron 2 CpG9-dinucleotide (CpG9) (coordinates chr6: 35,609,542) was significantly associated with higher HbA1c (β = 0.535, p = 0.003), with a medium to large effect size (R² = 0.143, R = 0.378). Dotted line on the x-axis indicates target HbA1c of 7.0%. b Greater percent DNA methylation of CpG9 was also significantly associated with higher LDL (β = 0.344, p = 0.037) with small to medium effect size (R² = 0.040, R = 0.201). Dotted line on the x-axis indicates target LDL of 100 mg/dL. c Greater percent methylation of the FKBP5 intron 2 CpG7-dinucleotide (CpG7) (coordinates chr6: 35,609,628) was significantly associated with higher BMI (β = 0.516, p = 0.001) with medium to large effect size (R² = 0.227, R = 0.476). Dotted line on the x-axis indicates a BMI cut-off for obesity at ≥ 30 kg/m². d Greater percent DNA methylation of CpG7 was also significantly associated with higher WC (β = 0.403, p = 0.006) with medium to large effect size (R² = 0.123, R = 0.350). Dotted lines on the x-axis indicate cut-offs for WC in metabolic syndrome criteria of ≥ 94 cm in men or ≥ 80 cm in women